Track topics on Twitter Track topics that are important to you
PolyXen® is an enabling technology for protein drug delivery. It uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides...
ImuXen® is a liposomal technology platform designed to improve the delivery and effectiveness of DNA, protein and polysaccharide vaccines. Proof of concept preclinical studies with a number of...
Our understanding of the epidemiology, pathophysiology, and management of premature ejaculation has increased substantially in recent years. Expert-agreed definitions of premat...
A new review argues that premature ejaculation—which has become the center of a multimillion dollar business—should not be classified as a male sexual dysfunction. By pointing to false assumptions...
UK biotechnology firm Ixchelsis has achieved positive clinical proof of concept (POC) for IX-01, its oral oxytocin receptor antagonist being developed to treat premature ejaculation (PE).
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.Related Posts:Promising Early Res...
Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice toda...
UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.Related Posts:Immunotherapy for Previously Treated Advance...
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with
Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced
Premature ejaculation is one of the prevalent disorders in men; almost one out of three men between 18 and 59 years old have this disorder with its leading sequel such as lack of self-confidence, anxi...
Four premature ejaculation (PE) subtypes are distinguished on the basis of the duration of the intravaginal ejaculation latency time (IELT), its course in life, and frequency of complaints. Since the ...
BACKGROUND This study aimed to investigate the association between changes in serum 5-hydroxy tryptamine (5-HT) concentrations and improvement in clinical symptoms in primary premature ejaculation wit...
Premature ejaculation (PE) is the most prevalent male sexual dysfunction. In the last few years, several pharmacologic approaches for oral or topical treatment of PE have been studied.